ESMO Congress | Conference

Dr. Ledermann Discusses Olaparib in Ovarian Cancer

October 1st 2014

Jonathan Ledermann, BSc, MD, FRCP, Professor of Medical Oncology in the UCL Cancer Institute, University College London, discusses health-related quality of life during olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer and a BRCA mutation.

Dr. Saab on a Phase II Study of the Oncolytic Virus Reolysin for Pancreatic Cancer

September 30th 2014

Tanios Bekaii-Saab, MD, discusses the results of a phase II study of the oncolytic virus reolysin in the first-line treatment metastatic adenocarcinoma of the pancreas.

Durable Responses Observed with Nivolumab in Previously Treated mRCC

September 30th 2014

Durable responses were obtained with the immune checkpoint inhibitor nivolumab, with a manageable safety profile, in a phase II dose-ranging trial conducted in patients with previously treated metastatic renal cell carcinoma (mRCC).

New Data Provide Insight Into Optimal Pre-Chemo Treatments for mCRPC

September 30th 2014

The combination of abiraterone acetate and prednisone has demonstrated a statistically significant improvement in overall survival (OS) for men with metastatic castration-resistant prostate cancer (mCRPC) who had not received prior treatment with chemotherapy

Dabrafenib/Trametinib Combo Improves Survival Over Vemurafenib in Phase III COMBI-v Trial

September 30th 2014

Patients with unresectable melanoma had a significant improvement in the odds of survival when treated in first line with a combination of BRAF and MEK inhibitors, as opposed to anti-BRAF monotherapy

Expanded 80405 Study Mutation Analysis Fails to Resolve Targeted Therapy Quandary in mCRC

September 30th 2014

All patients with metastatic colorectal cancer should undergo RAS mutation testing to ensure optimal patient selection for EGFR inhibitor therapy.

Dr. Motzer on a Phase II Trial of Nivolumab for mRCC

September 30th 2014

Robert J. Motzer, MD, attending physician, Memorial Sloan Kettering Cancer Center, provides an overview of a phase II study of nivolumab for the treatment of patients with clear cell metastatic renal cell carcinoma.

Combination BRAF, MEK Inhibition "New Standard" for Previously Untreated BRAF-Mutant Melanoma

September 29th 2014

Inhibiting BRAF and MEK at the same time improves progression-free survival (PFS) more so than BRAF inhibition alone in patients with BRAF V600 mutation-positive metastatic melanoma, according to results of a phase III placebo-controlled trial.

Pembrolizumab Shows Promise in Advanced Gastric Cancer

September 29th 2014

In patients with advanced gastric cancer expressing PD-L1, pembrolizumab (Keytruda) has robust antitumor activity and an acceptable safety profile

Crizotinib Highly-Effective in ROS1-Rearranged NSCLC

September 29th 2014

Treatment with crizotinib (Xalkori) demonstrated an overall response rate (ORR) of 72% in patients with ROS1-rearranged non–small cell lung cancer (NSCLC), according to phase I data presented at the 2014 ESMO Congress and published in The New England Journal of Medicine.

Dr. Weber on Nivolumab Versus Chemotherapy in Advanced Melanoma

September 29th 2014

Jeffrey S. Weber, MD, PhD, discusses the results of a phase III study of nivolumab compared with investigator's choice chemotherapy for the treatment of patients with advanced melanoma after prior anti-CTLA-4 therapy.

Nivolumab Beats Chemotherapy as Second-Line Treatment for Advanced Melanoma

September 29th 2014

Treatment with nivolumab (Opdivo) demonstrated superior objective response rates (ORR) and longer durations of response compared with chemotherapy in a phase III trial of patients with previously treated advanced metastatic melanoma, reported Jeffrey Weber, MD, at the 2014 ESMO Congress.

Dr. Galbraith Discusses Phase I/II Results for AZD9291 in Advanced NSCLC

September 29th 2014

Susan Galbraith, MD, PhD, head, Oncology Innovative Medicine, AstraZeneca, discusses updated data from the ongoing phase I/II AURA study looking at AZD9291 for NSCLC.

CLEOPATRA Trial Update Shows Dramatic OS Benefit

September 28th 2014

Dual HER2 blockade with pertuzumab and trastuzumab plus chemotherapy for the treatment of HER2-positive metastatic breast cancer improved median OS by almost 16 months over standard first-line therapy.

Dr. Swain Discusses the Final OS Analysis from the CLEOPATRA Study

September 28th 2014

Sandra M. Swain, MD, discusses final overall survival analysis from the CLEOPATRA study of first-line pertuzumab, trastuzumab, and docetaxel for the treatment of patients with HER2-positive metastatic breast cancer.

Cediranib Combined With Chemotherapy Improves PFS in Advanced Cervical Cancer

September 28th 2014

Cediranib improved response rate and median PFS when added to conventional chemotherapy in a phase II study of patients with relapsed or metastatic cervical cancer.

Pembrolizumab Yields Durable Responses in Advanced NSCLC

September 28th 2014

Almost 60% of patients with advanced non–small cell lung cancer experienced tumor shrinkage when treated with the PD-L1 inhibitor pembrolizumab.

Vintafolide Added to Docetaxel Improves Survival in Folate Receptor-Positive NSCLC

September 28th 2014

Vintafolide in combination with docetaxel showed improvements in PFS and OS compared with single-agent docetaxel as second-line treatment of patients with folate receptor–positive NSCLC.

Dr. Kluger on a Phase I Trial of Concurrent Nivolumab and Ipilimumab

September 28th 2014

Harriet Kluger, MD, associate professor of medicine, Yale Cancer Center, discusses the results from a phase I trial of nivolumab and ipilimumab for the treatment of patients with advanced melanoma.

Anamorelin Improves Appetite, Slows Weight Loss in Lung Cancer

September 27th 2014

Patients with advanced lung cancer had improved appetite, less weight loss, and a significant increase in lean body mass when treated with the ghrelin agonist anamorelin.

NEXT PAGE
PREVIOUS PAGE